Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advent's Life Science Fund Attracts UK Government Backing

This article was originally published in The Pink Sheet Daily

Executive Summary

Advent Venture Partners Raises £70 million for new life sciences fund in Europe.

You may also be interested in...



Proposed U.K. Budget Boost To Benefit Drug Industry

Amid drastic cuts in public-sector spending, the new U.K. government wants tax and regulatory changes to improve the environment for Big Pharma and biotech.

Proposed U.K. Budget Boost To Benefit Drug Industry

Amid drastic cuts in public-sector spending, the new U.K. government wants tax and regulatory changes to improve the environment for Big Pharma and biotech.

Cancer Research Technology Ltd.: Biopharma's Gateway to Cancer-Focused Academic Research

Cancer Research Technology - the technology transfer arm of Cancer Research UK, the world's largest charity - has long moved beyond simply commercializing and managing the IP generated by the half billion in research funding provided by Cancer Research UK to five core research institutes across the UK, as well as to researchers at dozens of other universities and organizations. CRT has a growing, 85-strong in-house drug discovery capability which is being expanded with the help of a five-year, £7 million ($11 million) grant from Cancer Research UK - and it's this that lured in AstraZeneca and another industry collaborator, Cephalon.

Related Content

Topics

UsernamePublicRestriction

Register

PS071492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel